Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 16Recruiting 5Unknown 3Terminated 3Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 87Gastrointestinal 19Thoracic 5CNS 4Tumor-Agnostic 3Gynecologic 3Head & Neck 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 3Carcinoma 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Trastuzumab × Tumor-Agnostic × Clear all
NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
104 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡